Edenor reported a 10% year-over-year revenue increase and a 94% rise in EBITDA (excluding CAMMESA) for Q2 2026, demonstrating strong operational recovery. However, net earnings dropped due to a one-time gain last year. The company's $780 million bid for Metrogas, if approved, could diversify Edenor's operations and drive medium-term growth, though integration risks remain. Despite a deeply discounted valuation compared to the sector, further upside depends on regulatory approvals and successful execution of growth catalysts, supporting a continued 'Hold' rating.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Pomerantz LLP is investigating Cellebrite DI Ltd. for potential securities fraud following the company's Q2 2026 financial report, which showed Annual Recurring Revenue (ARR) below guidance and a lowered full-year ARR forecast. The company also abrup...
